新天藥業(002873.SZ)與匯倫生物簽訂增資協議 完成第一期增資3000萬元
格隆匯3月29日丨新天藥業(002873.SZ)公佈,公司董事會於2020年3月5日收到控股股東貴陽新天生物技術開發有限公司(“新天生物”)以書面形式送達的《關於提請貴陽新天藥業股份有限公司增加2020年第一次臨時股東大會臨時提案的函》,提議將《關於對參股公司增資暨關聯交易的議案》作為臨時提案提交公司2020年第一次臨時股東大會審議。公司於2020年3月17日召開2020年第一次臨時股東大會,審議通過了《關於對參股公司增資暨關聯交易的議案》,同意公司以自有資金8000萬元人民幣對參股公司上海匯倫生物科技有限公司(“匯倫生物”)進行增資,增資完成後,公司將持有匯倫生物9.1743%的股權。
根據公司2020年第一次臨時股東大會決議,2020年3月26日,公司與匯倫生物簽訂了《上海匯倫生物科技有限公司增資協議》,並按照增資協議約定完成了第一期增資,第一期增資額為3000萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.